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Abstract  
Purpose: To compare the levels of aldose reductase enzyme (ALR), intercellular 
adhesion molecule-1 (ICAM-1), and vascular endothelial growth factor (VEGF) in 
the anterior lens capsule of diabetic versus non-diabetic patients. 
Setting: Alexandria main university hospital, Egypt 
Design: Prospective case-control study 
Methods: This study enrolled 200 eyes of 200 patients undergoing cataract 
extraction; 51 eyes have proliferative diabetic retinopathy (PDR), 49 eyes have 
non-proliferative diabetic retinopathy (NPDR), and 100 eyes of non-diabetics. 
The anterior lens capsules were obtained by performing femtolaser assisted 
capsulorhexis. Concentrations of ALR, ICAM-1 and VEGF in the lens capsule 
specimens were measured using human enzyme-linked immunosorbent assay. 
Results: The mean ALR, ICAM-1 and VEGF levels in the anterior capsule of 
diabetic group were 2.84 ± 0.51ng/ml, 87.73 ± 22.84 pg/ml, and 75.53 ± 14.95 
pg/ml, respectively. While in the non-diabetic group they were 1.44 ± 0.17 ng/ml, 
35.45 ± 2.8 pg/ml, and 33.55 ± 5.47 pg/ml, respectively. Comparing the 
concentrations of these mediators, both the PDR and NPDR groups had 
significantly higher levels compared to the non-diabetic eyes (p<0.001). In 
addition, eyes with PDR had significantly higher levels of these mediators 
compared to eyes with NPDR (p<0.001).   
Conclusion: The concentrations of ALR, ICAM-1, and VEGF in the anterior lens 
capsule of diabetic patients are significantly higher than those from non-
diabetics. A significantly higher level of three mediators in eyes with PDR 
4 
 
compared to those with NPDR might allow the use of them as a biomarker for 
severity of diabetic retinopathy. 
. 
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INTRODUCTION 
Diabetes mellitus (DM) is currently a global epidemic which can affect the 
eye by several mechanisms with cataract and diabetic retinopathy being the most 
common leading causes of diabetes related visual loss.1 Many changes in the 
retina, retinal vasculature, lens, cornea, and iris have been associated with DM.2  
Diabetic cataract pathogenesis is believed to be multifactorial though the 
exact mechanism remains speculative. Many studies suggested a direct link 
between aldose reductase (ALR) and diabetic cataract development as ALR is 
considered a key enzyme in diabetic cataract formation and progression.3 As a 
result, the inhibition of ALR has been considered as a potential target for 
prevention and treatment of diabetes related complications.4 ALR has also a 
detoxification role, as it specifically metabolizes toxic aldehydes, such as 
hydroxynonenal (HNE), 3-deoxyglucosone, and methylglyosal. However, these 
aldehydes arise in large quantities from pathological conditions connected with 
oxidative stress, as in hyperglycemia, and are intermediates for the formation of 
advanced glycation end products (AGEs).5  
Vascular endothelial growth factor (VEGF) is a potent vasoactive cytokine 
that is upregulated under local hypoxic states as in diabetes, causing increased 
vascular permeability due to endothelial tight junction disruption resulting in 
extravasation of fluid and retinal edema.6 It also stimulates stasis and stickness of 
blood constitutes in the microvessels of the retina which lead to blood retinal barrier 
(BRB) breakdown.7 Another key inflammatory cytokine that becomes upregulated 
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in DM is intercellular adhesion molecule-1 (ICAM-1).8 This cytokine has been 
incriminated in many diabetes mellitus related complications. 
The aim of the present study is to compare the levels of ALR, VEGF, and 
ICAM-1 in the anterior capsule of diabetes mellitus cataract patients compared to 
non-diabetic senile cataract patients, as well as to assess the correlation of these 
biomarkers levels with the development and progression of cataract and diabetic 
retinopathy. 
METHODS 
The study was performed at Alexandria main university hospital between 
November 2015 through April 2017, Alexandria, Egypt. The study adhered to the 
tenets of the Declaration of Helsinki. Ethical committee approval will be obtained 
and the patients will be managed according to the ethical guidelines of Alexandria 
University. 
           Patients with visually significant cataract undergoing cataract surgery 
were eligible for enrollment. Visually significant cataract was defined by: any 
LOCS III grading ≥2 using the slit lamp-based Lens Opacities Classification 
System III (LOCS III), BCVA <20/40, cataract as the primary cause of vision 
impairment, and self-reported vision of fair or worse.  Both type 2 diabetic 
patients with varying levels of DR and duration of diabetes between 10 and 15 
years but with HbA1c less than 7.5% as well as non-diabetic patients were 
included. Patients undergoing anti-inflammatory treatment and those with 
systemic disorders including cancer as well as other chronic inflammatory 
diseases were excluded from the study. Patients who had other ocular 
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pathologies, such as pseudoexfoliation syndrome, high myopia > -6.00 diopters, 
glaucoma, uveitis, trauma, previous ocular surgery, previous intravitreal injection, 
and any retinopathy other than DR were also excluded from the study. Also, high 
risk PDR patients and patients with past history or currently have diabetic 
macular edema were excluded. 
          Circular anterior capsules, approximately 5.5 mm in diameter, with 
attached lens epithelial cells (LECs) were obtained by femtolaser assisted 
technique after docking (Lensx, Alcon Laboratories, Inc) then the capsules were 
collected with capsulorhexis forceps (Kawai Capsulorhexis Forceps; Asico, 
USA). Lens capsule specimens were rinsed with phosphate buffered saline (1X 
PBS), homogenized at 4 °C in PBS (pH 7.4) containing protease inhibitor cocktail 
to prevent auto-oxidation. Next, the homogenates were centrifuged at 4°C for 5 
minutes at 5000 xg. The supernatant was collected, aliquoted and stored at -
80°C until biochemical analysis was ready to be performed. Concentrations of 
ALR, ICAM-1 and VEGF were measured using human enzyme-linked 
immunosorbent assay (ELISA) kits (CUSABIO, USA, Catalog #: CSB – E16266h; 
CUSABIO, USA, Catalog #: CSB – E04574h and RayBio®, Norcross GA, USA, 
Catalog #: ELH-VEGF respectively) according to the manufacturer’s protocol. 
The optical density of each sample was determined using a microplate reader at 
450 nm with the correction wavelength set at 540 nm or 570 nm. The 
concentration of ALR was calculated based on standards and expressed in 
ng/ml, while the concentration of ICAM1 and VEGF were expressed in pg/ml. 
The amounts of ALR, ICAM-1 and VEGF in each sample were determined in 
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duplicate in each experimental set of plates. The lysate was used for the ELISA 
assay without prior dilution according to preliminary testing so that sample values 
fell within the range of the standard curves for each parameter. The ELISA 
assays used for this study have high sensitivity and excellent specificity for 
detection of each of the three parameters. No significant cross-reactivity or 
interference between human ALR, ICAM-1 or VEGF and analogues or other 
cytokines was observed.  
        Statistical analysis: The Statistical Package for Social Sciences for Windows 
(SPSS Inc., PASW Statistics, version 18) was used for statistical analysis, and 
findings were considered to be statistically significant if P < 0.05. The differences 
in the expression of ALR, ICAM-1, and VEGF between the DM and control 
groups were analyzed by Student’s t-test, Mann-Whitney U-test, and Pearson’s 
Chi-square test, as appropriate. The correlations among ALR, ICAM-1, and 
VEGF expression were analyzed by Spearman’s rank correlation test. The 
receiver operator characteristic (ROC) curve was used to determine the optimal 
cut-off value of ALR, ICAM-1and VEGF expressed in the LECs, according to the 
coordinates of the cut-off point of the ROC curve that was closest to the 
coordinate (0, 1). The odds ratios of the expression of ALR, ICAM-1 and VEGF in 
the LECs were also evaluated as risk factors associated with the progression of 
cataract in type 2 diabetes between the DM and the control groups as well as 
between proliferative and non-proliferative diabetic retinopathy subgroups.  
 
Results 
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          A total of 200 patients were eligible for inclusion in this study. They were 
divided into two main groups. The first group included 100 eyes of 100 patients 
who were diabetic for ten years and had visually significant cataracts. This group 
was further subdivided into two subgroups: one included 49 eyes diagnosed with 
non-high-risk PDR and the other included 51 eyes diagnosed with NPDR. The 
second main group included 100 eyes of 100 non-diabetic patients with visually 
significant cataracts (control group). Patients in group 1 included 44 women and 
46 men with mean age 50 ± 7.3 years. Group 2 (control group) included 50 
women and 50 men with an average age of 53.4 ± 5.2 years. There were no 
significant differences between the groups as regard age and gender. 
         The mean ICAM-1 level from the anterior capsule was 87.73 ± 22.84 pg/ml 
in the diabetic group and 35.45 ± 2.81 pg/ml in the control group (p<0.001). The 
mean ALR level was 2.84 ± 0.51 ng/ml in diabetic group and 1.44 ± 0.17 ng/ml in 
the control group (p<0.001). The mean VEGF level was 75.53 ± 14.95 pg/ml in 
diabetic group and 33.55 ± 5.47 pg/ml in the control group (p<0.001). The 
difference in levels remained significant when comparing the control group to 
eyes with either PDR or NPDR separately (Tables 1 and 2)  
        ROC curve analysis and odds ratio of ICAM-1, ALR, and VEGF expression 
in LECs: Following analysis of the ROC curve, the optimal cut-off values of 
ICAM-1, ALR, and VEGF expression in LECs needed to differentiate between 
diabetic and non-diabetic cataract groups were found to be >42.5 pg/ml, >1.8 
ng/ml, and >32.5 pg/ml respectively.  
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The AUC for ICAM-1 was 0.985 (p<0.001) with a sensitivity of 96%, specificity of 
97%, positive predictive value (PPV) of 97%, and negative predictive value 
(NPV) of 96%. The AUC for ALR was 0.988 (p<0.001) with a sensitivity of 92%, 
specificity of 100%, PPV of 100%, and NPV of 92.6%. The AUC for VEGF was 
0.983 (p<0.001) with a sensitivity of 97%, specificity of 66%, PPV of 74%, and 
NPV of 95.7% (Figure 1).  
         When the ROC curve was analyzed to predict the cut off values of ICAM-1, 
ALR and VEGF expression in LECs comparing PDR and NPDR subgroups, the 
values were >90 pg/ml,  >2.8 ng/ml and >72.5 pg/ml respectively. ICAM-1 had 
the highest sensitivity and specificity as a predictor of proliferative changes in 
diabetic cataract (98% and 100% respectively) (Figures 2 and 3). 
Moreover, the odds ratios for the expression of ALR and VEGF in the 
LECs were 11.086 -fold and 27.547-fold higher in the PDR group, respectively, 
than in the NPDR group. Thus, these mediators may be regarded as important 
risk factors during the progression of cataract in diabetic patients (Table 3) 
 
Discussion 
          The development of DR is a complex process involving many mediators 
including different growth factors, genetic predisposition, and immune response.9 
In order to elucidate the relation between the immune cells, vascular endothelial 
cells, and the role of ALR enzyme in the lens capsule of DR patients, this study 
investigated the expression of ALR, VEGF and ICAM-1 in anterior lens capsules 
from diabetic versus non-diabetic patients undergoing cataract surgery. The 
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study found that the levels of ALR, VEGF, and ICAM-1 were significantly higher 
in the diabetic group compared to the non-diabetic control group. Moreover, the 
level of these mediators was also significantly higher in the anterior lens capsule 
of eyes with PDR compared to those with NPDR. 
           The elevated levels of ALR seen with worsening levels of DR correlate 
with the common understanding of its role in diabetic cataract formation. ALR is a 
rate-limiting enzyme of the polyol pathway. ALR-mediated polyol accumulation 
has been shown to lead to sorbitol accumulation in diabetic eyes causing 
increased osmotic pressure, alterations in cell membrane permeability, edema, 
and damage to cells of the crystalline lens.10 Intracellular accumulation of sorbitol 
primarily occurs under hyperglycemic conditions which in turn leads to 
acceleration of cataract formation and progression.11 Therefore, the increased 
ALR levels may correlate with the presumed higher levels of chronic 
hyperglycemia that are likely found in PDR compared to NPDR and non-diabetic 
controls. 
 Correlation between increasing levels of ALR with the development and 
progression of DR is still disputable. Previous studies which tried to investigate 
the associations between ALR gene polymorphism and DR ended up with 
controversial results. One study recruited 3512 DM patients with DR and 4319 
DM patients without DR. The study found that ALR C (−106) T polymorphism 
was not associated with an increased risk of DR. However, subgroup analysis 
demonstrated a genetic association.12 Another study conducted by Abhary et al 
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found that variations within the AKR1B1 gene were highly associated with 
diabetic retinopathy development irrespective of ethnicity.13 
Increased levels of VEGF with worsening DR seen in the current study 
may also correlate with the hyperglycemic environment. Hyperglycemia induced 
oxidative stress leads to formation of advanced glycation end products (AGEs).7 
Recent studies suggest that AGEs interact with plasma membrane localized 
receptors for AGEs (RAGE) to alter intracellular signaling, gene expression, 
release of pro-inflammatory molecules and free radicals. As a result, AGEs may 
alter cellular functions in LECs under local hypoxic conditions as seen in 
diabetics, leading to increased levels of inflammatory cytokines, AGEs and 
reactive oxygen species. Consequently, this may induce VEGF gene expression 
which promotes angiogenesis and vascular permeability.6,14 That is why VEGF 
nowadays is an attractive target for many studies aiming at halting DM related 
ocular complications.15  
The higher levels of ICAM-1 with worsening DR as seen in this study also 
correlates with the fact that its upregulation in inflammatory states. One of the 
key inflammatory events involved in the BRB alteration appears to be increased 
expression of endothelial adhesion molecules including ICAM-1 in response to 
some of these cytokines.8 ICAM-1 promotes retinal vascular leukocyte adhesion, 
increased vascular permeability, and capillary closure in combination with 
elevated VEGF levels.16,17 In fact, VEGF may potentiate the expression of ICAM-
1 in the retinal vasculature.18 Increased levels of soluble ICAM-1 in the serum of 
diabetic patients with severe complications have been documented.19 In addition, 
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it is elevated in both the aqueous humor and vitreous of diabetic patients.20,21 
More recently, a study by Hiller et al correlated increased aqueous humor ICAM-
1 with severity of diabetic macular edema.22  
 The current study has several limitations. While ALR, VEGF, and ICAM-1 
are significantly elevated in the anterior lens capsules of eyes with DR, this study 
was not designed to determine if these mediators are directly involved in the 
pathogenesis of diabetic cataracts or DR. It is possible that these mediators may 
merely reflect the severity of hyperglycemia, inflammation and ischemia in eyes 
with DR. The duration of diabetes and standardized scoring of DR severity as 
indicators of glycemic control were also not addressed in this study, which may 
have affected the expression of the studied mediators. In any case, it should be 
considered that only patients with HbA1c less than 7.5 mg/dl were enrolled in the 
study to ensure a good glycemic control. This can reflect a good control of 
diabetes three months preceding the surgery. Another potential limitation was the 
fact that a “visually significant” cataract was determined by the surgeon and not 
based on standard criteria. It is possible that variations in the severity of the 
cataract in the different studied groups could have also affected the results. In 
conclusion, the levels of ALR, VEGF and ICAM-1 in the anterior lens capsule are 
significantly higher in diabetic compared with non-diabetic eyes. The fact that the 
levels of all three were significantly higher in PDR eyes compared to NPDR eyes 
suggests that these mediators may serve as important biomarkers for severity of 
diabetic retinopathy. Future studies will be necessary to determine whether the 
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elevated levels of these mediators are directly responsible for diabetic cataract 
formation and worsening DR or a reaction to the intraocular milieu. 
 
WHAT WAS KNOWN 
 
-A direct link seems to be present between aldose reductase (ALR) and 
diabetic cataract development as ALR is considered a key enzyme in diabetic 
cataract formation and progression. 
-Vascular endothelial growth factor (VEGF) is upregulated under local 
hypoxic states as in diabetes 
-Intercellular adhesion molecule-1 (ICAM-1) is another key inflammatory 
cytokine that becomes upregulated in diabetes mellitus. 
 
WHAT THIS PAPER ADDS 
  
 -Levels of ALR, VEGF and ICAM-1 in anterior lens capsules are 
significantly higher in eyes from diabetic patients compared to the non-diabetic. 
Moreover, the level of these mediators was also significantly higher in the 
anterior lens capsule of eyes with proliferative diabetic retinopathy (PDR) 
compared to those with non-proliferative diabetic retinopathy (NPDR). 
-The study of these inflammatory mediators may help for a better 
understanding of diabetes-related eye complications. In other words, the 
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presence of these mediators in significant amount in diabetic eyes might indicate 
an association between them and the pathogenesis of diabetic eye disease. 
-The levels of these three mediators may serve as important biomarkers 
for severity of diabetic retinopathy.  
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Figure legends:  
Figure (1): ROC curve for ICAM – 1, ALR and VEGF to predict diabetes  
 
Figure (2): ROC curve for ICAM – 1, ALR and VEGF to predict PDR 
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Figure (3): Comparison between the studied subgroups according to the 
different parameters 
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Table (1): Comparison of ICAM-1, aldose reductase, and VEGF in diabetics 
versus non-diabetics.  
 
 Diabetes (n= 100) 
Control 
(n= 100) P 
ICAM – 1(pg/ml) 87.73 ± 22.84 35.45 ± 2.81 <0.001* 
Aldose reductase 
(ng/ml) 2.84 ± 0.51 1.44 ± 0.17 <0.001
* 
VEGF(pg/ml) 75.53 ± 14.95 33.55 ± 5.47 <0.001* 
Normally quantitative data was expressed in mean ± SD and was compared 
using student t-test. *: Statistically significant at p ≤ 0.05.  ICAM-1: intercellular 
adhesion molecule-1. VEGF: vascular endothelial growth factor. pg: picogram. 
ng: Nanogram. 
 
Table 2: Comparison of ICAM-1, aldose reductase, and VEGF in non-proliferative 
diabetic retinopathy versus proliferative diabetic retinopathy versus non-diabetic 
controls. 
 NPDR (n= 51) 
PDR 
(n= 49) 
Control 
(n= 100) p 
ICAM – 1(pg/ml) 71.57±16.74 104.54 ±14.75 35.45 ± 2.81 <0.001* 
Sig. between groups  p1<0.001*,p2<0.001*,p3<0.001*  
Aldose reductase (ng/ml) 2.55  ±0.41 3.15  ± 0.43 1.44  ±0.17 <0.001* 
Sig. between groups p1<0.001*,p2<0.001*,p3<0.001*  
VEGF(pg/ml) 65.98  ±11.57 85.46  ±11.13 33.55  ±5.47 <0.001* 
Sig. between groups p1<0.001*,p2<0.001*,p3<0.001*  
Normally quantitative data was expressed in mean ± SD and was compared using F value for 
ANOVA test, Post Hoc Test (LSD). 
p1: p value for comparing between NPDR and PDR 
p2: p value for comparing between NPDR and Control 
p3: p value for comparing between PDR and Control 
*: Statistically significant at p ≤ 0.05 
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Table (3): Odds Ratio (OR) analysis between NPDR and PDR subgroups  
 
 NPDR (n= 51) 
PDR 
(n= 49) P OR 95% CI (LL-UL)  No % No % 
ICAM         
≤ 90 51 100 1 2.0 <0.001*   >90 0 0.0 48 98.0 - - 
Aldose         
≤ 2.8 43 84.3 16 32.7 0.001*   >2.8 8 15.7 33 67.3 11.086 4.2 – 29.0 
VEGF        
≤ 72.5 43 84.3 8 16.3 0.001*   >72.5 8 15.7 41 83.7 27.547 9.4 – 80.3 
 
 
